Related references
Note: Only part of the references are listed.
Letter
Medicine, General & Internal
Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged ≥60 Years
Noa Eliakim-Raz et al.
Summary: This study focuses on evaluating the anti-S IgG antibody levels before and after the administration of a third dose of the BNT162b2 vaccine in individuals aged 60 and older in Israel.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Article
Cell Biology
Coinfection with influenza A virus enhances SARS-CoV-2 infectivity
Lei Bai et al.
Summary: The upcoming flu season in the Northern Hemisphere coinciding with the COVID-19 pandemic poses a potential threat to public health. Research shows that influenza A virus infection significantly enhances the infectivity of SARS-CoV-2, leading to increased viral load and more severe lung damage in coinfected individuals. Preventing influenza A infection is crucial in controlling the spread of COVID-19.
CELL RESEARCH (2021)
Article
Medicine, General & Internal
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study
Noam Barda et al.
Summary: A study using data from Israel's largest health-care organization showed that a third dose of the BNT162b2 mRNA vaccine is effective in preventing individuals from severe COVID-19-related outcomes, compared to receiving only two doses at least 5 months ago. The effectiveness of the third dose in preventing hospital admission was 93%, severe disease 92%, and COVID-19-related death 81%.
LANCET (2021)
Share Paper
